Efficacy and safety of active vitamin D supplementation in chronic spontaneous urticaria patients
Mohamed AA, Hussein MS, Salah EM, Eldemery A, Darwish MM, Ghaith DM, Attala RA, El Borolossy R
Published in Journal of Dermatological Treatment
Methodology
Case-control plus randomized placebo-controlled trial: 77 CSU patients versus 67 healthy controls, with patients randomized to alfacalcidol 0.25 µg daily or placebo for 12 weeks.
Key Findings
Serum 25(OH)D was significantly lower in CSU patients and negatively correlated with urticaria severity; alfacalcidol raised 25(OH)D and significantly lowered IL-6, hsCRP and TNF-alpha versus placebo.
Conclusions
Active vitamin D (alfacalcidol) may be a useful, well-tolerated add-on therapy in chronic spontaneous urticaria.
Limitations
Single centre, modest sample, inflammatory markers rather than hard symptom endpoints emphasised, active vitamin D analogue not equivalent to cholecalciferol.
Supplements Studied
After alfacalcidol administration, the study group showed significant higher level of 25(OH) D compared to the placebo group. In addition, the mean serum level of IL6, hsCRP and TNFα significantly decreased.
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Academic/institutional
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.